The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer: A meta-analysis.
The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer: A meta-analysis.
复制标题
预处理血小板与淋巴细胞比预测宫颈癌患者的临床结局：一项荟萃分析。
DOI：
10.1097/md.0000000000012897
复制
发表时间：
2018-10
期刊：
影响因子：
1.6
通讯作者：
Liu Q
中科院分区：
文献类型：
--
作者：
Ma JY;Ke LC;Liu Q
血小板与淋巴细胞比率（PLR）已被报道在多种类型的癌症中具有重要的预后价值。然而，其在宫颈癌患者中的预后价值仍存在争议。我们进行了一项荟萃分析，以评估预处理PLR在宫颈癌中的预后价值。我们检索了MEDLINE、EMBASE和科克伦数据库，以确定评估宫颈癌患者预处理PLR预后意义的研究。终点为总生存期（OS）、无病生存期（DFS）、无进展生存期（PFS）和临床病理学参数。所有统计分析均使用Stata 13.0进行。共纳入12项研究，包括3668例宫颈癌患者。PLR升高与OS差[风险比（HR）：1.56，95%置信区间（CI）：1.32-1.85，P <0.001]和DFS/PFS（HR = 1.56; 95% CI = 1.26-1.94; P <0.001）显著相关。 PLR升高与淋巴管浸润（+）、淋巴结转移（+）、肿瘤大小（> 4cm）、分级（G3）密切相关。 治疗前PLR可作为宫颈癌患者预后不良的预测性生物标志物。
The platelet-to-lymphocyte ratio (PLR) has been reported to possess significant prognostic value in multiple types of cancer. However, its prognostic value in patients with cervical remains controversial. We conducted a meta-analysis to evaluate the prognostic value of pretreatment PLR in cervical cancer. We searched the MEDLINE, EMBASE, and Cochrane databases to identify studies evaluating the prognostic significance of the pretreatment PLR in patients with cervical cancer. The end points were overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathological parameters. All statistical analyses were conducted with Stata 13.0. A total of 12 studies comprising 3668 patients with cervical cancer were included. Elevated PLR was significantly correlated with poor OS [hazard ratio (HR): 1.56, 95% confidence interval (CI): 1.32–1.85, P < .001] and DFS/PFS (HR = 1.56; 95% CI = 1.26–1.94; P < .001). In addition, elevated PLR was highly correlated with lymphovascular space invasion (+), lymph node metastasis (+), tumor size (>4 cm), grade (G3). The pretreatment PLR could serve as a predicative biomarker of poor prognosis for patients with cervical cancer.